T-cell receptor gene therapy for cancer
$2,008,917ZIAFY2018CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications & trials
Paper 34116844Paper 33741731Paper 33558725Paper 31959727Paper 30646017Paper 29669936Paper 29528339Paper 29368612Paper 27037253Paper 26429982Paper 24329789Paper 24142051
Abstract
We have identified the genetic sequences of TCRs that target tumor antigens. We are tested genetically engineered T cells that express these TCRs for the treatment of patients with cancer. Our research is focused and on understanding response and resistance to these treatments with the aim of using this knowledge to develop more effective treatments. This work includes the discovery of technologies to identify biomarkers of response, to enhance the efficacy of therapeutic T cells, and to target new tumor antigens.
View original record on NIH RePORTER →